AFP
ARNA

Ausdal Financial Partners’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Ausdal Financial Partners’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,050
Closed -$18K – 284
2016
Q3 		$18K Hold
1,050
– – 0.01% 264
2016
Q2 		$18K Hold
1,050
– – 0.01% 260
2016
Q1 		$21K Hold
1,050
– – 0.01% 230
2015
Q4 		$20K Buy
+1,050
New +$21.4K 0.01% 730

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Ausdal Financial Partners's ARNA Position: Q4 2016 in Review

Ausdal Financial Partners sold out of Arena Pharmaceuticals Inc (ARNA) in Q4 2016, closing a stake of 1,050 shares — an estimated $18K sold.

Ausdal Financial Partners first reported a position in ARNA in Q4 2015 and held it in 4 quarters. The position peaked at $21K in Q1 2016. 128 funds tracked by Wall St. Rank hold ARNA as of Q4 2016.

  • Ausdal Financial Partners reported no remaining Arena Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 1,050 Arena Pharmaceuticals Inc shares in Q4 2016, an estimated $18K.
  • Ausdal Financial Partners first reported a position in Arena Pharmaceuticals Inc in Q4 2015 and held it in 4 quarters.
  • Ausdal Financial Partners's Arena Pharmaceuticals Inc position peaked at $21K in Q1 2016.
  • 128 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q4 2016.

Based on Ausdal Financial Partners's 13F filing for Q4 2016, filed 23 Jan 2017.